SummaryThe therapeutic action of a drug depends on its ability to engage with its molecular target in vivo. However, current drug discovery strategies quantify drug levels within organs rather than determining the binding of drugs directly to their specific molecular targets in vivo. This is a particular problem for assessing the therapeutic potential of drugs that target malignant tumors where access and binding may be impaired by disrupted vasculature and local hypoxia. Here we have used triple-negative human breast cancer cells expressing β2-adrenoceptors tagged with the bioluminescence protein NanoLuc to provide a bioluminescence resonance energy transfer approach to directly quantify ligand binding to a G protein-coupled receptor in vivo using a mouse model of breast cancer.

Among class A G protein-coupled receptors (GPCR), the human adenosine A 2A receptor (hA 2A AR) remains an attractive drug target. However, translation of A 2A AR ligands into the clinic has proved challenging and an improved understanding of A 2A AR pharmacology could promote development of more efficacious therapies. Subtype-selective fluorescent probes would allow detailed realtime pharmacological investigations both in vitro and in vivo. In the present study, two families of fluorescent probes were designed around the known hA 2A AR selective antagonist preladenant (SCH 420814). Both families of fluorescent antagonists retained affinity at the hA 2A AR, selectivity over all other adenosine receptor subtypes and allowed clear visualization of specific receptor localization through confocal imaging. Furthermore, the Alexa Fluor 647-labeled conjugate allowed measurement of ligand binding affinities of unlabeled hA 2A AR antagonists using a bioluminescence resonance energy transfer (NanoBRET) assay. The fluorescent ligands developed here can therefore be applied to a range of fluorescence-based techniques to further interrogate hA 2A AR pharmacology and signaling.